CN106309416A - 二芳基硫醚衍生物的给药方案 - Google Patents

二芳基硫醚衍生物的给药方案 Download PDF

Info

Publication number
CN106309416A
CN106309416A CN201610590854.9A CN201610590854A CN106309416A CN 106309416 A CN106309416 A CN 106309416A CN 201610590854 A CN201610590854 A CN 201610590854A CN 106309416 A CN106309416 A CN 106309416A
Authority
CN
China
Prior art keywords
compound
alkyl
dose
prodrug
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610590854.9A
Other languages
English (en)
Chinese (zh)
Inventor
P·盖尔盖伊
E·勒冈诺克斯
E·沃尔斯特罗姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN106309416A publication Critical patent/CN106309416A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201610590854.9A 2010-05-06 2011-05-05 二芳基硫醚衍生物的给药方案 Pending CN106309416A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10162082 2010-05-06
EP10162082.1 2010-05-06
CN2011800227113A CN102917698A (zh) 2010-05-06 2011-05-05 二芳基硫醚衍生物的给药方案

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2011800227113A Division CN102917698A (zh) 2010-05-06 2011-05-05 二芳基硫醚衍生物的给药方案

Publications (1)

Publication Number Publication Date
CN106309416A true CN106309416A (zh) 2017-01-11

Family

ID=42236590

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610590854.9A Pending CN106309416A (zh) 2010-05-06 2011-05-05 二芳基硫醚衍生物的给药方案
CN2011800227113A Pending CN102917698A (zh) 2010-05-06 2011-05-05 二芳基硫醚衍生物的给药方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011800227113A Pending CN102917698A (zh) 2010-05-06 2011-05-05 二芳基硫醚衍生物的给药方案

Country Status (12)

Country Link
US (4) US20130210924A1 (https=)
EP (1) EP2566473B1 (https=)
JP (3) JP2013525469A (https=)
KR (1) KR20130098885A (https=)
CN (2) CN106309416A (https=)
AU (1) AU2011249789B2 (https=)
BR (1) BR112012028248A2 (https=)
CA (1) CA2794607A1 (https=)
EA (1) EA201201515A1 (https=)
ES (1) ES2562416T3 (https=)
MX (1) MX2012012925A (https=)
WO (1) WO2011138398A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519539B (zh) * 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
BR112015019197A2 (pt) 2013-02-20 2017-07-18 Kyorin Seiyaku Kk tratamento de doença de enxerto versus hospedeiro em pacientes transplantados
AU2022214268A1 (en) * 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1561331A (zh) * 2001-09-27 2005-01-05 杏林制药株式会社 二芳基硫醚衍生物及其加成盐和免疫抑制剂
CN1681776A (zh) * 2002-09-19 2005-10-12 杏林制药株式会社 氨基醇衍生物及其加成盐以及免疫抑制剂
CN101257899A (zh) * 2005-09-09 2008-09-03 诺瓦提斯公司 自身免疫疾病的治疗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
BRPI0407658A (pt) 2003-02-18 2006-02-21 Kyorin Seiyaku Kk derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico
ATE449069T1 (de) 2003-08-28 2009-12-15 Novartis Pharma Gmbh Aminopropanolderivate
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
KR20070085465A (ko) * 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
PL2278960T5 (pl) * 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Schemat dawkowania dla selektywnego agonisty receptora sip1
WO2010020609A1 (en) * 2008-08-18 2010-02-25 Novartis Ag Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
JP5657565B2 (ja) * 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
TW201028143A (en) * 2008-12-22 2010-08-01 Novartis Ag Dosage regimen for a S1P receptor agonist

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1561331A (zh) * 2001-09-27 2005-01-05 杏林制药株式会社 二芳基硫醚衍生物及其加成盐和免疫抑制剂
CN1681776A (zh) * 2002-09-19 2005-10-12 杏林制药株式会社 氨基醇衍生物及其加成盐以及免疫抑制剂
CN101257899A (zh) * 2005-09-09 2008-09-03 诺瓦提斯公司 自身免疫疾病的治疗

Also Published As

Publication number Publication date
WO2011138398A1 (en) 2011-11-10
AU2011249789B2 (en) 2015-03-19
US20170119702A1 (en) 2017-05-04
US20130210924A1 (en) 2013-08-15
JP6290963B2 (ja) 2018-03-07
CA2794607A1 (en) 2011-11-10
EA201201515A1 (ru) 2013-08-30
US20140336265A1 (en) 2014-11-13
MX2012012925A (es) 2012-12-17
BR112012028248A2 (pt) 2016-08-02
EP2566473B1 (en) 2016-01-06
JP2016183159A (ja) 2016-10-20
JP2018100280A (ja) 2018-06-28
ES2562416T3 (es) 2016-03-04
CN102917698A (zh) 2013-02-06
JP2013525469A (ja) 2013-06-20
KR20130098885A (ko) 2013-09-05
AU2011249789A1 (en) 2012-12-13
JP6615247B2 (ja) 2019-12-04
EP2566473A1 (en) 2013-03-13
US20180161290A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
US20250262171A1 (en) Dosage regimen for a s1p receptor agonist
RU2478384C2 (ru) Курс лечения с использованием агониста рецептора s1p
JP6615247B2 (ja) ジアリールスルフィド誘導体の投与レジメン
AU2018202854B2 (en) Dosage regimen for a S1P receptor agonist
AU2013204099A1 (en) Dosage regimen for a S1P receptor agonist

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180806

Address after: Tokyo, Japan, Japan

Applicant after: Kyorin Pharmaceutical Co., Ltd.

Address before: Basel

Applicant before: Novartis Ag

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170111